10.08.14
The CE mark has been granted to Masimo Corp.’s Oxygen Reserve Index (ORI), a noninvasive and continuous parameter designed to provide insight into a patient’s oxygen reserve when they are receiving supplemental oxygen. When used in conjunction with ORI, Masimo’s rainbow SET Pulse CO-Oximeters with the latest MX-5 circuit board can now measure 11 parameters through its noninvasive optical rainbow sensor technology.
Pulse oximetry provides noninvasive and continuous visibility to arterial blood oxygenation in hypoxia (less than normal oxygenation) and normoxia (normal oxygenation). During supplemental oxygen administration, clinicians often use the partial pressure of oxygen, which is intermittent and delayed, to monitor levels of hyperoxia (higher than normal oxygenation). Between invasive sampling, changes in oxygen pressure cannot be assessed and therefore unexpected hypoxia or unintended hyperoxia can occur.
ORI provides real-time visibility to oxygenation status in moderate hyperoxic range. ORI is intended to supplement, not replace, pulse oximetry monitoring and oxygen pressure measurements. As an “index” parameter with a unit-less scale between 0.0 and 1.0, ORI can be trended and has optional alarms to notify clinicians of changes in a patient’s oxygen reserve.
In patients receiving supplemental oxygen such as those in surgery, conscious sedation, or the intensive care unit, ORI may provide an advance warning of an impending hypoxic state, or an indication of an unintended hyperoxic state. In this way, ORI may enable proactive interventions to avoid hypoxia and unintended hyperoxia, the company claims.
“ORI is another example of Masimo’s commitment to take noninvasive patient monitoring to new sites and applications,” said Masimo Founder and CEO Joe Kiani. “We believe ORI will have significant applications during surgical procedures, intubation and procedural sedation, among others, and can help clinicians improve patient outcomes by keeping patients in the optimal oxygenation zone to help reduce risk for both hypoxia and hyperoxia.”
ORI is available in Europe, but is not available in the United States.
Masimo is based in Irvine, Calif., and makes noninvasive patient monitoring technology.
Pulse oximetry provides noninvasive and continuous visibility to arterial blood oxygenation in hypoxia (less than normal oxygenation) and normoxia (normal oxygenation). During supplemental oxygen administration, clinicians often use the partial pressure of oxygen, which is intermittent and delayed, to monitor levels of hyperoxia (higher than normal oxygenation). Between invasive sampling, changes in oxygen pressure cannot be assessed and therefore unexpected hypoxia or unintended hyperoxia can occur.
ORI provides real-time visibility to oxygenation status in moderate hyperoxic range. ORI is intended to supplement, not replace, pulse oximetry monitoring and oxygen pressure measurements. As an “index” parameter with a unit-less scale between 0.0 and 1.0, ORI can be trended and has optional alarms to notify clinicians of changes in a patient’s oxygen reserve.
In patients receiving supplemental oxygen such as those in surgery, conscious sedation, or the intensive care unit, ORI may provide an advance warning of an impending hypoxic state, or an indication of an unintended hyperoxic state. In this way, ORI may enable proactive interventions to avoid hypoxia and unintended hyperoxia, the company claims.
“ORI is another example of Masimo’s commitment to take noninvasive patient monitoring to new sites and applications,” said Masimo Founder and CEO Joe Kiani. “We believe ORI will have significant applications during surgical procedures, intubation and procedural sedation, among others, and can help clinicians improve patient outcomes by keeping patients in the optimal oxygenation zone to help reduce risk for both hypoxia and hyperoxia.”
ORI is available in Europe, but is not available in the United States.
Masimo is based in Irvine, Calif., and makes noninvasive patient monitoring technology.